Detalhe da pesquisa
1.
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids.
Immunity
; 47(6): 1182-1196.e10, 2017 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29262351
2.
Whole-genome sequencing of African Americans implicates differential genetic architecture in inflammatory bowel disease.
Am J Hum Genet
; 108(3): 431-445, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33600772
3.
Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study.
Gastroenterology
; 165(4): 963-975.e5, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37499955
4.
Early Life and Childhood Environmental Exposures, More Than Genetic Predisposition, Influence Age of Diagnosis in a Diverse Cohort of 2952 Patients With IBD.
Clin Gastroenterol Hepatol
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38309494
5.
Environmental Factors Associated with Risk of Crohn's Disease Development in the CCC-GEM Project.
Clin Gastroenterol Hepatol
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38759825
6.
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study.
Am J Gastroenterol
; 2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095692
7.
The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile Acids.
Immunity
; 52(3): 571, 2020 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32187521
8.
Pattern Recognition Receptor Signaling and Cytokine Networks in Microbial Defenses and Regulation of Intestinal Barriers: Implications for Inflammatory Bowel Disease.
Gastroenterology
; 162(6): 1602-1616.e6, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149024
9.
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol
; 21(11): 2908-2917.e10, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36280102
10.
Altered Gut Microbiome Composition and Function Are Associated With Gut Barrier Dysfunction in Healthy Relatives of Patients With Crohn's Disease.
Gastroenterology
; 163(5): 1364-1376.e10, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35850197
11.
Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation.
Gastroenterology
; 163(3): 685-698, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643175
12.
Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses.
Clin Gastroenterol Hepatol
; 21(9): 2211-2221, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35863682
13.
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.
Am J Gastroenterol
; 118(11): 2005-2013, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37207314
14.
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 381(13): 1201-1214, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553833
15.
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Clin Gastroenterol Hepatol
; 20(2): 465-467.e2, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421628
16.
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Clin Gastroenterol Hepatol
; 20(12): 2858-2867.e5, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35276329
17.
Epithelial TLR4 Signaling Activates DUOX2 to Induce Microbiota-Driven Tumorigenesis.
Gastroenterology
; 160(3): 797-808.e6, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33127391
18.
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Gastroenterology
; 160(5): 1570-1583, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33359090
19.
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
Gastroenterology
; 160(7): 2291-2302, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33610533
20.
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus.
Clin Gastroenterol Hepatol
; 20(11): 2619-2627.e1, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35189386